Phase 0/I/II Cancer Prevention Clinical Trials Program Clinical Trials

Title Intervention NCT ID Sponsorsort descending Status
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection S-adenosyl-L-methionine disulfate p-toluene-sulfonate, placebo, laboratory biomarker analysis, immunoenzyme technique, high performance liquid chromatography NCT00513461 Chao Family Comprehensive Cancer Center Completed
Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers linaclotide acetate, placebo, pharmacological study, laboratory biomarker analysis NCT01950403 Mayo Clinic Completed
Sulindac Capsules Compared With Sulindac Tablets in Healthy Volunteers sulindac, pharmacological study NCT00343629 Mayo Clinic Completed
Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast Afimoxifene, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration NCT03063619 M.D. Anderson Cancer Center Recruiting
Natural History of Lung Nodules Seen on CT Scans From Participants at High-Risk of Developing Lung... medical chart review, computed tomography, computer-aided detection/diagnosis NCT01540552 M.D. Anderson Cancer Center Completed
Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia sulindac, placebo NCT00368927 National Cancer Institute (NCI) Completed
Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch... Laboratory Biomarker Analysis, Naproxen, Placebo NCT02052908 National Cancer Institute (NCI) Active, not recruiting
Resveratrol in Postmenopausal Women With High Body Mass Index resveratrol, laboratory biomarker analysis NCT01370889 National Cancer Institute (NCI) Completed
Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission Berberine Chloride, Laboratory Biomarker Analysis, Placebo NCT02365480 National Cancer Institute (NCI) Active, not recruiting
Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer Laboratory Biomarker Analysis, Nelipepimut-S Plus GM-CSF Vaccine, Sargramostim NCT02636582 National Cancer Institute (NCI) Active, not recruiting